Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]

The changing landscape of AML

Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany

The changing landscape of AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )

CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL

Dr Othman Al-Sawaf - Univesity of Cologne, Cologne, Germany

CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL ( Dr Othman Al-Sawaf - Univesity of Cologne, Cologne, Germany )

Comment: Enfortumab vedotin is an effective therapy and important development...

Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak

Comment: Enfortumab vedotin is an effective therapy and important development for urotherial cancer patients ( Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak )

Cutting-edge cancer care at the Miami Cancer Institute

Dr Miguel Villalona - Miami Cancer Institute, Miami, USA

Cutting-edge cancer care at the Miami Cancer Institute ( Dr Miguel Villalona - Miami Cancer Institute, Miami, USA )

Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable...

Dr Mark Roschewski - National Cancer Institute, Bethesda, USA

Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable responses in R/R DLBCL and indolent lymphoma ( Dr Mark Roschewski - National Cancer Institute, Bethesda, USA )

Acalabrutinib monotherapy shows significant benefit in relapsed or refractory...

Dr Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

$Acalabrutinib monotherapy shows significant benefit in relapsed or refractory chronic lymphocytic leukaemia ( Dr Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )$

CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo...

Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA

CALGB 90601: Comparing gemcitabine and cisplatin with bevacizumab to placebo for metastatic urothelial carcinoma ( Dr Jonathan Rosenberg - Memorial Sloan-Kettering Cancer Institute, New York, USA )

Maintenance pembrolizumab vs placebo for metastatic urothelial cancer

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

Maintenance pembrolizumab vs placebo for metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )

NILE: Should we give everything to patients with unresectable locally advanced...

Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA

NILE: Should we give everything to patients with unresectable locally advanced or metastatic urothelial cancer? ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )

CheckMate-142: Updated data from MSI high metastatic colon cancer patients

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

CheckMate-142: Updated data from MSI high metastatic colon cancer patients ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

Margetuximab for the treatment of HER2-positive breast cancer

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston...

Margetuximab for the treatment of HER2-positive breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )

The future of PARP inhibitors in metastatic breast cancer

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston...

The future of PARP inhibitors in metastatic breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer